BergenBio Fundamentale Forhold (BGBIO)

[polygon]

Hva mener du fundamentalt har endret seg til det bedre siden du skrev dette for et år siden?

@vcp

Fy f!#* for en tragisk lesning!

Bgbio. gratulerer med å ha flådd et utall investorer.

Vi har blitt holdt for narr over flere år.

Eller er det bare at aksjene og tegningsrettene har blitt et tradersirkus som har ført til at du er i pluss som gjør at du har endret innstilling (igjen)?

[vcp]

Vi som har sittet lenge har åpenbart blitt rævkjørt og ikke blitt hørt. Her er covid det beste eksempelet. Vi var mange som var i dialog med selskapet rundt dette. Men det var fånyttes. Det er ikke mulig å endre på.

Det meste er endret hva angår struktur, ressursbruk. En ledelse med en ganske annerledes og direkte tilnærming til studier og markedet enn det som tidligere har vært tilfelle. Bruk en time to å les selskapets presentasjoner siste 2 år. Det ble ryddet i skapene. Mye mer selektiv.

Bemcentinib vet vi har effekt, STK11 er nøkkelen her. Så er det til syvende og sist ledelsen i selskapet og styret som må forvalte dette på en strategisk og smart måte.

[polygon]

@vcp

Bemcentinib vet vi har effekt

Det vet vi vel ikke? Det de har en fase I/II som kan gi ytterligere signaler om effekt, med planlagt avlesning om to år. Et tidspunkt som de pt. ikke er finansiert til?

[Mrt]

Resultatene viser en meget positiv effekt…
Du får lese litt på de siste rapportene så finner du info der
Med disse resultatene kommer det nok en partner på plass i slutten av 2024, så da er det penger nok skal du se

[TekBot]

BerGenBio ASA – Disclosure of large shareholding

On 5 January 2024, Investinor Direkte AS sold 10,861,235 shares in BerGenBio ASA (the “Company”). Following the disposal of shares, Investinor Direkte AS owns 124,070,385 shares in the Company, representing a total of 4.6% of the Company’s issued shares and voting rights (based on 2,688,689,214 shares issued by the Company). In addition, Investinor Direkte AS holds 107,215,810 warrants to subscribe for shares in the Company.

This announcement is made in accordance with Section 4-2 of the Norwegian Securities Trading Act.
…

Vis børsmeldingen

Kilde

[seifisk]

Når siste frist for å innløse wattenes i Bergenbio?

[LarsErik64]

tegningsrettene innløses i perioden fra 1. april 2024 til 15. april 2024 kl 16.30 (CEST) Det vil bli informert fra selskapet også på newsweb NewsWeb

[seifisk]

Takk for svar

[LarsErik64]

Bare hyggelig🙂

Mye tyder på at det vil bli rush på rettene frem mot april… tror nå jeg.

[TekBot]

BerGenBio ASA: Invitation to fourth quarter 2023 results webcast

Bergen, Norway, 6 February 2024 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, will announce its results for the fourth quarter 2023 on
…

Vis børsmeldingen

Wednesday 14 February 2024.

BerGenBio’s senior management team will provide a business update at 10:00 am
CET.

The presentation will webcast live. To participate in the webcast please
register in the following link:

BerGenBio Q4 2023 webcast registration
link (https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fforms.off
ice.com%2Fe%2FjDmiXn9rCD&data=05%7C02%7Crune.skeie%40bergenbio.com%7C71b892a04002
4e35831b08dc11204242%7C2b50b422ca6d42af9fc0741b248bb071%7C0%7C0%7C638404077460438
276%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiL
CJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=JkXs41rqj%2F85XiPLueKDwCilRQBq%2FC9OuJqjOR%2B
cdyk%3D&reserved=0)

A recording of the webcast will be available at www.bergenbio.com in the
Investors/Financial Reports
section (Financial reports - BerGenBio) shortly
afterwards.

The fourth quarter financial report and presentation will also be made available
on the Company’s website in the Investors/Financial Reports
section (Financial reports - BerGenBio) from 7:00am CET
the same day.

Warrants

As part of the Rights Issue offering completed in June 2023, BerGenBio issued
Warrants to the subscribers in the offering. The Warrants are tradable under the
ticker BGBIS on the Oslo Stock Exchange up to 8 April 2024. The holders of the
Warrants can exercise the Warrants 1 - 15 April 2024. Additional information
about the Warrants is available on the Company’s website in the
Investors/Warrants (https://www.bergenbio.com/investors/investor
-relations/warrants) section.

-End-

Contacts

Martin Olin, CEO BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK.

The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to MAR
article 17 and section 5-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections

Bergen, Norway, February 7, 2024, - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, today announced that Dr. Mirella Spalluto of the
…

Vis børsmeldingen

University of Southampton today presented “Investigating the effects of AXL
inhibition during respiratory viral infections” during the 6th Forum on
Respiratory Infections in Glasgow, Scotland.

The data presented by Dr. Spalluto showed bemcentinib had activity in human in
vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza
and rhinovirus. In these models, bemcentinib downregulated IL-6 and IL-8, two
important inflammatory cytokines associated with the severity of hospitalized
respiratory infections.

Clinically, patients with viral respiratory infections can develop acute
respiratory distress syndrome (ARDS), a life-threatening condition. In ARDS
patients, cytokines - a type of inflammatory protein - are released bringing
neutrophils to the lung to fight infection. These proteins, however, can leak
into blood vessels, traveling through the body resulting in inflammation of
other organs which may lead to organ failure.

Cristina Oliva, MD, Chief Medical Officer at BerGenBio commented on the
relevance of these new data: “The findings of cytokine down-regulation in
preclinical models align with samples from patients treated with bemcentinib in
previous clinical studies of hospitalized COVID-19. These data indicate that
bemcentinib may be a helpful addition to supportive care in patients with ARDS
resulting from a variety of common viral infections. The need for new
therapeutics in this patient population is acute, with the morality rate from
viral ARDS estimated at between 27-45%. We look forward to conducting
additional preclinical evaluation of bemcentinib’s activity in severe
respiratory infections to further bolster our understanding in this important
area.”

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Jan Lilleby

jl@lillebyfrisch.no

About Bemcentinib

Bemcentinib is a potentially first-in-class, potent and highly selective
inhibitor of the tyrosine kinase AXL. Extensive studies confirm the ability to
combine bemcentinib with immune checkpoint inhibitors, chemotherapies and
targeted therapies with the goal of improving a patient’s immune response and
delaying the development of chemoresistance. Bemcentinib is currently being
investigated in combination with immune checkpoint inhibition and chemotherapy
in first line NSCLC patients harboring mutations in the STK11 gene, a known
prognostic factor of poor response to existing therapies.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visitwww.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[polygon]

[LarsErik64]

I og med at du vet hva du snakker om, Polygon, så hadde det vært interessant å høre hva du tenker om disse datane. Er det relevans, eller nyhet for nyhetens interesse.

Flott om du deler hva du tenker.

[Lebo]

Antyder at Bergenbio-legemiddel kan brukes i behandlingen av alvorlige...

[Lebo]

BGBIO: BerGenBio Announces New Preclinical Data Indicating Broadened...

[Hakon]

Og vips så var ikke covid sporet bortkastet likevel

– Funnene av nedregulering av cytokiner i prekliniske modeller stemmer overens med prøver fra pasienter som er behandlet med bemcentinib i tidligere kliniske studier av covid-19 på sykehus, sier sier Cristina Oliva, medisinsk direktør Bergenbio, i meldingen.

[TekBot]

BerGenBio’s Fourth Quarter 2023 Results: Focused Strategy Gathers Momentum

Bergen (Norway), February 14, 2024 - BerGenBio ASA (OSE: BGBIO), a clinical
-stage bio-pharmaceutical company developing novel, selective AXL kinase
inhibitors for severe unmet medical needs, today announced financial results for
…

Vis børsmeldingen

the quarter ended December 31, 2023, and provided a business update.

Highlights, including post period

· Phase 1b part of BGBC016 (1L NSCLC STK11m) progressed as planned with no new
safety signals identified.
· Regulatory approvals received from European countries for Phase 2a part of
BGBC016 (1L NSCLC STK11m) allowing initiation in H1 2024 in accordance with
guidance.
· Significant reduction of operating expenses - NOK 43.9 million for the
fourth quarter 2023, down from NOK 76.8 million from same period in 2022, a
reduction of 43%, reflecting a laser focused strategy on NSCLC.
· Year-end cash position of NOK 156.4 million and a net cash flow in Q4 2023
of NOK -11.8 million including gross proceeds of NOK 8.9 million from exercise
of warrants in Q4.
· Multiple Phase 2 bemcentinib data presented at prestigious oncology
meetings, including ESMO, SITC and ASH.
· New preclinical data in models of severe respiratory infections continues to
support the potential of bemcentinib beyond NSCLC.

Martin Olin, Chief Executive Officer of BerGenBio:

“As previously guided, we expect to initiate the Phase 2a part of the BGBC016
trial in 1L NSCLC STK11m patients during the first half of 2024. Bemcentinib
represents a novel therapeutic option for NSCLC patients harboring mutations in
the STK11 gene and we are gratified to see the medical community’s interest and
support in exploring bemcentinib. The BGBC016 clinical trial is our highest
priority and continues to progress as expected.”

“Our cost discipline coupled with our recently executed warrant offering
provides the company with funding through the end of 2024 and potentially into
the second half of 2025 if all outstanding warrants are exercised in April
2024.”

Presentation and Financial Report

The Q4 2023 Financial Report is attached to this stock exchange announcement
and the Report and the Q4 2023 presentation are available at the Company’s
website (Financial reports - BerGenBio).

Webcast details

BerGenBio’s senior management team will provide a business update today at 10:00
am CET. The presentation will webcast live. To participate in the webcast please
use the following registration link:

BerGenBio Q4 webcast
(office.com) (Microsoft Forms
-QEn0CM7P0uPzintVGMr
-Gxc6nJw_YlNh1teJiuU8DNUMFpXWFFUWVdLTkFZMkRNV1JJRTRWVVBXVy4u)

A recording of the webcast will be available at www.bergenbio.com in the
Investors/Financial Reports
section (Financial reports - BerGenBio) shortly
afterwards.

Exercise of Warrants

· Outstanding warrants (ticker BGBIS) can be exercised during the final
warrant exercise window from April 1-15, 2024.
· For additional information on the upcoming Warrant Exercise window of April
1-15, 2024, please refer to: https://www.bergenbio.com/investors/investor
-relations/warrants

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in clinical development for STK11 mutated
NSCLC and preclinical development for severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visitwww.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and subject to the disclosure requirements pursuant to
section 5-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BerGenBios resultater for fjerde kvartal 2023: Fokusert strategi gir momentum

Bergen (Norge), 14. februar 2024 - BerGenBio ASA (OSE: BGBIO) er et
biofarmasøytisk selskap i klinisk fase som utvikler nye, selektive AXL
-kinasehemmere for alvorlige udekkede medisinske behov. Selskapet la i dag frem
…

Vis børsmeldingen

økonomiske resultater for kvartalet som ble avsluttet 31. desember 2023, og ga
oppdateringer på driften.

Viktigste hendelser i perioden, inkludert tiden etter kvartalsslutt

· Fase 1b-delen av BGBC016 (1L NSCLC STK11m) går som planlagt uten at det er
identifisert nye risikoer
· Regulatoriske godkjenninger ble mottatt fra europeiske land for fase 2a
-delen av BGBC016 (1L NSCLC STK11m) som tillater oppstart i første halvår 2024,
i samsvar med selskapets annonserte plan
· Betydelig reduksjon av driftskostnader - 43,9 millioner kroner for fjerde
kvartal 2023, ned fra 76,8 millioner kroner fra samme periode i 2022, en
reduksjon på 43 %, noe som reflekterer en laserfokusert strategi for NSCLC
· Kontantbeholdning ved årsslutt på 156,4 millioner kroner og en netto
kontantstrøm i fjerde kvartal 2023 på -11,8 millioner kroner, inkludert
bruttoproveny på 8,9 millioner kroner fra utøvelse av tegningsretter i fjerde
kvartal
· Flere fase 2-data om bemcentinib presentert på prestisjefylte onkologimøter,
inkludert ESMO, SITC og ASH
· Nye prekliniske data i modeller for alvorlige luftveisinfeksjoner fortsetter
å underbygge potensialet til bemcentinib utover NSCLC

Martin Olin, administrerende direktør i BerGenBio:

• Som nevnt tidligere forventer vi å starte fase 2a-delen av BGBC016-studien i
  1L NSCLC STK11m-pasienter i løpet av første halvdel av 2024. Bemcentinib
  representerer en ny behandling for NSCLC-pasienter som har mutasjoner i STK11
  -genet, og vi er glade for å se det medisinske miljøets interesse og støtte i å
  utforske bemcentinib. Den kliniske studien, BGBC016, er vår høyeste prioritet og
  fremgangen er som forventet.

• Vår kostnadsdisiplin kombinert med vår nylig innhentede kapital fra utøvelse
  av tegningsretter gir selskapet finansiering ut slutten av 2024 og potensielt
  inn i andre halvdel av 2025 dersom alle utestående tegningsretter utøves i april

Presentasjon og finansiell rapport

Finansiell rapport for fjerde kvartal 2023 er vedlagt denne børsmeldingen, og
rapporten og presentasjonen for fjerde kvartal 2023 er tilgjengelig på
selskapets hjemmeside: Financial reports - BerGenBio.

Mer om webcasten

Ledelsen i BerGenBio vil gi en presentasjon i dag kl. 10:00 CET. Presentasjonen
gjøres gjennom en live webcast. For å delta i webcasten, bruk følgende
registreringslenke:

Microsoft Forms
-Gxc6nJw_YlNh1teJiuU8DNUMFpXWFFUWVdLTkFZMkRNV1JJRTRWVVBXVy4u

Et opptak av webcasten vil være tilgjengelig på www.bergenbio.com under
Investors/Financial Reports kort tid etter presentasjonens slutt.

Utøvelse av tegningsretter

· Utestående tegningsretter (ticker BGBIS) kan utøves i løpet av det siste
utøvelsesvinduet fra 1. til 15. april 2024.
· For ytterligere informasjon om det kommende utøvelsesvinduet 1. til 15.
april 2024, vennligst se: https://www.bergenbio.com/investors/investor
-relations/warrants

Kontakter

Martin Olin, administrerende direktør, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, finansdirektør, BerGenBio ASA

rune.skeie@bergenbio.com

Pressekontakt

Jan Lilleby

jl@lillebyfrisch.no

Om BerGenBio ASA

BerGenBio er et biofarmasøytisk selskap i klinisk fase som fokuserer på å
utvikle transformative legemidler rettet mot AXL som en potensiell hjørnesten i
behandlingen av aggressive sykdommer, inkludert kreft og alvorlige
luftveisinfeksjoner. Selskapet fokuserer på sin proprietære hovedkandidat,
bemcentinib, en potensielt førsteklasses selektiv AXL-hemmer i klinisk utvikling
for STK11-mutert NSCLC og preklinisk utvikling for alvorlige
luftveisinfeksjoner.

BerGenBio har hovedkontor i Bergen, med et datterselskap i Oxford. Selskapet er
notert på Oslo Børs (ticker: BGBIO). For mer informasjon, se www.bergenbio.com

Fremtidsrettede uttalelser

Denne børsmeldingen kan inneholde fremtidsrettede uttalelser, som i sin natur
ikke er historiske fakta, men er basert på ulike antagelser, hvorav mange er
basert på ytterligere antagelser. Disse antagelsene er i sin natur gjenstand for
mulig revidering i lys av betydelige kjente og ukjente risikoer, usikkerhet og
andre viktige faktorer. Slike risikoer, usikkerhetsmomenter, uforutsette
hendelser og andre viktige faktorer kan føre til at faktiske hendelser avviker
vesentlig fra forventningene som er uttrykt eller antydet i denne børsmeldingen
av slike fremtidsrettede uttalelser.

Denne informasjonen anses som innsideinformasjon i henhold til EUs
markedsmisbruksforordning og underlagt offentliggjøringskravene i henhold til
verdipapirhandelloven § 5-12.

Kilde

[Boms]

@TekBot

· Fase 1b-delen av BGBC016 (1L NSCLC STK11m) går som planlagt uten at det er
identifisert nye risikoer
· Regulatoriske godkjenninger ble mottatt fra europeiske land for fase 2a
-delen av BGBC016 (1L NSCLC STK11m) som tillater oppstart i første halvår 2024,
i samsvar med selskapets annonserte plan

On-track er good news

[TekBot]

BerGenBio ASA - Approval and publication of a prospectus supplement

Bergen 19 February 2024 - Reference is made to the stock exchange announcement
on 7 December 2023 regarding the approval and publication of a prospectus
prepared by BerGenBio ASA (the “Company”) for the listing of new shares to be
…

Vis børsmeldingen

issued by the Company (the “Prospectus”).

The Financial Supervisory Authority of Norway (Nw.: Finanstilsynet) has today
approved a prospectus supplement dated 19 February 2024 (the “Prospectus
Supplement”) to the Prospectus. The Prospectus Supplement has been prepared
inter alia in connection with the publication by the Company of its results for
the fourth quarter of 2023. The information contained in the Prospectus
Supplement shall be considered an integral part of, and is to be read together
with, the Prospectus. The Prospectus is available, and the Prospectus Supplement
will be made available, on the Company’s website:
Warrants - BerGenBio

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.no

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit www.bergenbio.com

This information is subject to the disclose requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde